Benchmark analyst Raymond Myers lowered its price target from $7 to $4, while it maintained a buy rating, on Synergetics SURG after further disappointment in F2Q.
In the report Benchmark said, "Following further disappointment in F2Q, Synergetics has transitioned to a value stock as we wait for confirmation of our long-term growth thesis. We substantially reduced our current year and F2014 forecasts in response to continued pressure in the legacy ophthalmic business and mixed OEM performance. Expanding Vitrectomy procedures and significant recent VersaVIT sales wins support longterm optimism; however, we anticipate this new business will be too small to meaningfully contribute until F20114."
Synergetics closed on Wednesday at $3.59.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in